In March 2020, mild signs and symptoms of coronavirus disease developed in a healthy 33-year-old
man in Hong Kong. His first infection did not produce virus neutralizing antibodies. …

Background A novel coronavirus of zoonotic origin (2019-nCoV) has recently been
identified in patients with acute respiratory disease. This virus is genetically similar to SARS …

The SARS-CoV-2 pandemic poses the greatest global public health challenge in a century.
Neutralizing antibody is a correlate of protection and data on kinetics of virus neutralizing …

Background and objective Few head‐to‐head evaluations of immune responses to different
vaccines have been reported. Methods Surrogate virus neutralization test (sVNT) antibody …

The mRNA vaccine Comirnaty and the inactivated vaccine CoronaVac are both available in
Hong Kong’s COVID-19 vaccination programme. We observed waning antibody levels in …

Backgrounds Influenza virus can survive on some surfaces, facilitating indirect person-to-person
transmission. Methods We collected swab samples weekly from commonly touched …

Methods Of the 360 participants who had received two doses of CoronaVac as part of our
previous study (3), 260 showed surrogate neutralization test (sVNT) results below 60% in their …

The Omicron variant is rapidly becoming the dominant SARS-CoV-2 virus circulating globally.
It is important to define reductions in virus neutralizing activity in the serum of convalescent …

The SARS-CoV-2 Omicron variant has demonstrated enhanced transmissibility and escape
of vaccine-derived immunity. Although first-generation vaccines remain effective against …

Background Transmission of SARS-CoV-2 from humans to other mammals, including pet
animals, has been reported. However, with the exception of farmed mink, there is no previous …